WO2018030881A3 - Utilisation d'hormone thyroïdienne pour le traitement d'une maladie choroïdienne - Google Patents

Utilisation d'hormone thyroïdienne pour le traitement d'une maladie choroïdienne Download PDF

Info

Publication number
WO2018030881A3
WO2018030881A3 PCT/KR2017/012501 KR2017012501W WO2018030881A3 WO 2018030881 A3 WO2018030881 A3 WO 2018030881A3 KR 2017012501 W KR2017012501 W KR 2017012501W WO 2018030881 A3 WO2018030881 A3 WO 2018030881A3
Authority
WO
WIPO (PCT)
Prior art keywords
thyroid hormone
treatment
choroidal disease
choroidal
disease
Prior art date
Application number
PCT/KR2017/012501
Other languages
English (en)
Korean (ko)
Other versions
WO2018030881A2 (fr
Inventor
윤성문
Original Assignee
윤성문
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 윤성문 filed Critical 윤성문
Publication of WO2018030881A2 publication Critical patent/WO2018030881A2/fr
Publication of WO2018030881A3 publication Critical patent/WO2018030881A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique contenant une hormone thyroïdienne pour la prévention ou le traitement d'une maladie choroïdienne ; un procédé de prévention ou de traitement d'une maladie choroïdienne par administration d'une hormone thyroïdienne ; et une nouvelle utilisation d'une hormone thyroïdienne pour la prévention ou le traitement d'une maladie choroïdienne.
PCT/KR2017/012501 2017-01-03 2017-11-06 Utilisation d'hormone thyroïdienne pour le traitement d'une maladie choroïdienne WO2018030881A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170000841A KR101782577B1 (ko) 2017-01-03 2017-01-03 맥락막 질환의 치료를 위한 갑상선 호르몬의 용도
KR10-2017-0000841 2017-01-03

Publications (2)

Publication Number Publication Date
WO2018030881A2 WO2018030881A2 (fr) 2018-02-15
WO2018030881A3 true WO2018030881A3 (fr) 2018-03-29

Family

ID=60035899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/012501 WO2018030881A2 (fr) 2017-01-03 2017-11-06 Utilisation d'hormone thyroïdienne pour le traitement d'une maladie choroïdienne

Country Status (2)

Country Link
KR (1) KR101782577B1 (fr)
WO (1) WO2018030881A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101782577B1 (ko) * 2017-01-03 2017-09-28 윤성문 맥락막 질환의 치료를 위한 갑상선 호르몬의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075032A (en) * 1995-02-01 2000-06-13 Allergan Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
WO2006031922A2 (fr) * 2004-09-15 2006-03-23 Ordway Research Institute Analogues d'hormones thyroidiennes et procedes d'utilisation correspondants
WO2009122180A1 (fr) * 2008-04-02 2009-10-08 Medical Research Council Dérivés de pyrimidine capables d’inhiber une ou plusieurs kinases
KR101782577B1 (ko) * 2017-01-03 2017-09-28 윤성문 맥락막 질환의 치료를 위한 갑상선 호르몬의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075032A (en) * 1995-02-01 2000-06-13 Allergan Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
WO2006031922A2 (fr) * 2004-09-15 2006-03-23 Ordway Research Institute Analogues d'hormones thyroidiennes et procedes d'utilisation correspondants
WO2009122180A1 (fr) * 2008-04-02 2009-10-08 Medical Research Council Dérivés de pyrimidine capables d’inhiber une ou plusieurs kinases
KR101782577B1 (ko) * 2017-01-03 2017-09-28 윤성문 맥락막 질환의 치료를 위한 갑상선 호르몬의 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHI, L. Z.: "Use of Z310 cells as an in vitro blood-cerebrospinal fluid barrier model: Tight junction proteins and transport properties", TOXICOLOGY IN VITRO, vol. 22, no. 1, 28 July 2007 (2007-07-28), pages 190 - 199, XP022393682 *

Also Published As

Publication number Publication date
WO2018030881A2 (fr) 2018-02-15
KR101782577B1 (ko) 2017-09-28

Similar Documents

Publication Publication Date Title
MX2021004431A (es) Procesos novedosos.
EP4223774A3 (fr) Composition pharmaceutique destinée à être utilisée dans le traitement ou la prévention d'une maladie liée à c5 et procédé de traitement ou de prévention d'une maladie liée à c5
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MX2019012884A (es) Terapia de combinacion.
CR20190531A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2019011608A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
WO2017022962A8 (fr) Composition pour la prévention ou le traitement d'une maladie immunitaire, comprenant un inhibiteur de la rip kinase en tant que principe actif
CR20190530A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
PH12016501548B1 (en) Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
MX2019012522A (es) Compuestos y metodos terapeuticos.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
WO2018030881A3 (fr) Utilisation d'hormone thyroïdienne pour le traitement d'une maladie choroïdienne
WO2020025657A9 (fr) Composition destinée à être utilisée dans la prévention et/ou le traitement de la muqueuse génito-urinaire
MX2019008603A (es) Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer.
WO2015165964A8 (fr) Traitement et prévention de la maladie d'alzheimer
MX2019004200A (es) Terapia de combinacion.
PH12020551620A1 (en) Compositions for preventing or treating dry eye
PH12020550549A1 (en) Compositions for preventing or treating lupus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17839898

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17839898

Country of ref document: EP

Kind code of ref document: A2